Core Insights - Addex Therapeutics announced that its partner Indivior has successfully advanced the GABAB positive allosteric modulator (PAM) program through IND enabling studies, marking the final preclinical development stage before clinical studies can commence [1][2] - Addex is eligible for payments up to USD 330 million based on the achievement of regulatory, clinical, and commercial milestones, along with tiered royalties on net sales ranging from high single digits to low double digits [2] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs for various neurological conditions [4] GABAB PAM Program - The GABAB PAM program is aimed at treating substance use disorders and has successfully completed preclinical safety and toxicity studies [2][3] - The activation of the GABAB receptor is clinically validated, with existing agonists like baclofen showing efficacy in multiple disease areas, although their use is limited due to side effects [3] - Novel PAMs are expected to provide efficacy with fewer adverse effects and less tolerance compared to direct agonists [3]

Core Insights - Addex Therapeutics has entered into an option- and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property related to mGlu5 inhibitors aimed at brain injury recovery [1][2] - The collaboration will focus on the preclinical validation of Addex's lead drug candidate, dipraglurant, which is an mGlu5 negative allosteric modulator [2][3] - The mGlu5 receptor is believed to play a significant role in brain plasticity and functional recovery following brain injuries such as strokes [4] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in novel small molecule allosteric modulators for neurological disorders [5] - The company's lead candidate, dipraglurant, is being evaluated for its potential in treating brain injury recovery, including post-stroke and traumatic brain injury [5] - Addex also has partnerships and programs targeting other neurological conditions, including a GABAB PAM program for chronic cough and a 20% equity interest in Neurosterix LLC [5]

Core Viewpoint - Addex Therapeutics reported its full-year 2024 financial results, highlighting progress in clinical development and a significant net profit from discontinued operations, primarily due to the sale of part of its business to Neurosterix [1][4][8]. Financial Performance - Total income for 2024 was CHF 410,000, a decrease of CHF 1.2 million from CHF 1.6 million in 2023 [4][11]. - Research and Development (R&D) expenses decreased to CHF 854,000 from CHF 1.2 million, while General and Administrative (G&A) expenses also decreased to CHF 2.3 million from CHF 2.7 million [4][12]. - The total operating loss increased to CHF 2.8 million in 2024 from CHF 2.2 million in 2023 [4][13]. - Net loss from continuing operations was CHF 4.9 million, an increase of CHF 2.4 million compared to CHF 2.5 million in 2023 [4][13]. - The company reported a net profit of CHF 7.1 million for the period, primarily due to a net profit from discontinued operations of CHF 12.0 million [9]. Corporate Developments - The company launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A funding to advance its preclinical portfolio [6][7]. - Indivior selected a GABAB PAM drug candidate for development in substance use disorders, while Addex selected its own GABAB PAM for chronic cough [2][6]. - Addex regained full control of its mGlu2 PAM asset, ADX71149, and repositioned dipraglurant for brain injury recovery [2][6]. Cash Position - Cash and cash equivalents decreased to CHF 3.3 million at the end of 2024 from CHF 3.9 million at the end of 2023, primarily due to cash used in operating activities [10].

Core Viewpoint - Addex Therapeutics will announce its Full-Year 2024 Financial Results on April 25, 2025, and provide a business update along with a review of its product pipeline during a teleconference and webcast [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4]. - The company has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4]. - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs targeting schizophrenia, mood disorders, and mild neurocognitive disorders [4]. - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [4].

Core Viewpoint - Addex Therapeutics has regained all development and commercialization rights to ADX71149 (JNJ-40411813) after the termination of its partnership with Janssen Pharmaceuticals, allowing the company to explore new therapeutic indications and potential partnerships for the drug [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2]. - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2]. - Addex also has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [2]. - The company holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [2]. Recent Developments - The termination of the partnership with Janssen Pharmaceuticals allows Addex to regain control over ADX71149, which has completed three Phase 2 studies and possesses a high-quality data package [2]. - The CEO of Addex expressed excitement about regaining control and mentioned ongoing evaluations for high-value therapeutic indications and discussions with potential partners [2].

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders and is advancing its own GABAB PAM program for chronic cough [4] - The company holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [4] Recent Developments - Dr. Robert Lütjens, Head of Discovery - Biology, will present a corporate update and discuss recent advances from Addex's CNS pipeline at the Swiss Equities Baader Conference [2][3] - The presentation is scheduled for January 10, 2025, at 11:40 CET in Bad Ragaz, Switzerland [3] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [4]

Financial Data and Key Metrics Changes - The company has made excellent progress in its GABAB positive allosteric modulator program, completing the R&D phase and delivering multiple drug candidates [6]. Business Line Data and Key Metrics Changes - A partner, Indivior, has selected a compound for development in substance use disorder and has initiated R&D enabling studies [6]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were provided in the available content. Company Strategy and Development Direction and Industry Competition - The company is focused on advancing its GABAB PAM preclinical program, indicating a strategic emphasis on substance use disorder treatments [6]. Management's Comments on Operating Environment and Future Outlook - Management has expressed confidence in the progress of their R&D programs and the selection of compounds for further development [6]. Other Important Information - The financial statements and press release were made available on the company's website prior to the conference call [4]. Q&A Session Summary - No specific questions and answers from the Q&A session were provided in the available content.

Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 2 Unaudited Interim Condensed Consolidated Statements of Profit or Loss for the three-month and nine-month periods ended September 30, 2024 and 2023 3 Unaudited Interim Condensed Consolidated Statements of Comprehensive Income or Loss for t ...

Core Viewpoint - Addex Therapeutics has selected a GABAB PAM drug candidate for development in substance use disorders and is initiating IND enabling studies while also seeking partners for later clinical development stages [2][3] Financial Performance - For Q3 2024, Addex reported a net loss of CHF 1.5 million, an improvement from a net loss of CHF 2.6 million in Q3 2023, primarily due to the sale of part of its business [7] - Total operating loss for Q3 2024 was CHF 622,000, down from CHF 749,000 in Q3 2023, reflecting a decrease in R&D and G&A expenses [3][13] - Cash and cash equivalents decreased to CHF 3.3 million as of September 30, 2024, from CHF 4.7 million a year earlier, attributed to cash used in operating activities [9] Income and Expenses - Income for Q3 2024 was CHF 59,000, a significant decrease from CHF 329,000 in Q3 2023, mainly due to the completion of a research agreement with Indivior [3][10] - R&D expenses decreased to CHF 205,000 in Q3 2024 from CHF 490,000 in Q3 2023, reflecting the completion of the research agreement [3][11] - G&A expenses were stable at around CHF 1.9 million for the nine-month periods ended September 30, 2024, and 2023, with a slight decrease in Q3 2024 [12] Discontinued Operations - During the nine-month period ended September 30, 2024, net profit from discontinued operations was CHF 12.0 million, primarily due to a net gain of CHF 14.0 million from the sale of part of the business [5][6] - The net profit for the nine-month period was CHF 8.3 million, driven by the profit from discontinued operations, offset by a net loss from continuing operations of CHF 3.7 million [6] Corporate Developments - Addex is advancing an independent GABAB PAM program for chronic cough while collaborating with Indivior on substance use disorders [2][17] - The company holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs [17]

Core Viewpoint - Addex Therapeutics reported a significant decrease in net results for the third quarter of 2024, with a net loss of CHF 1.5 million compared to a net profit of CHF 12.9 million in the previous quarter, primarily due to a nonrecurring gain from a business sale in the second quarter [2][3] Financial Performance - The provisional net loss for Q3 2024 was CHF 1.5 million, a decrease of CHF 14.4 million from the net profit of CHF 12.9 million in Q2 2024 [2] - For the nine-month period ending September 30, 2024, Addex reported a net profit of CHF 8.3 million, down from CHF 9.8 million for the six-month period ending June 30, 2024 [3] - As of September 30, 2024, Addex's cash position was CHF 3.3 million [3] Upcoming Events - Addex is scheduled to release its third quarter 2024 financial results on November 22, 2024, with a teleconference and webcast for investors and analysts [4]